Adalimumab in Adult Japanese Subjects With Moderate to Severe Chronic Plaque Psoriasis

Study Identifier
M04-688
CT.gov Identifier
NCT00338754
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Results Available

Scientific Result Summary
Available Language(s): English
Download document(s)

Study Details

Medical Condition
  • Dermatology - Psoriasis (PsO)
    • Study Drug
  • Human anti-TNF monoclonal antibody adalimumab/ up to 24 weeks
    • Phase
    CSR.ORG
    Sex
    Female & Male
    Age
    20+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    - Subject was age 20 or older and in good health (Investigator discretion) with a recent stable medical history. - Subject had a clinical diagnosis of psoriasis for at least 6 months, and had moderate to severe plaque psoriasis
    Exclusion Criteria:
    - Subject had previously received anti-TNF therapy. - Subject cannot discontinue systemic therapies and/or topical therapies for the treatment of psoriasis and cannot avoid UVA, UVB or PUVA phototherapy - Subject is taking or requires oral or injectable corticosteroids - Subject considered by the investigator, for any reason, to be an unsuitable candidate for the study - Female subject who is pregnant or breast-feeding or considering becoming pregnant

    Protocol Summary

    The purpose of the study is to assess the efficacy and safety of repeated administration of

    adalimumab in adult Japanese subjects with moderate to severe chronic plaque psoriasis.

    Study Locations

    Location
    Status
    Location
    Chubu, Japan
    Status
    Not applicable
    Location
    Chugoku, Japan
    Status
    Not applicable
    Location
    Hokkaido, Japan
    Status
    Not applicable
    Location
    Kanto, Japan
    Status
    Not applicable
    Location
    Kinki, Japan
    Status
    Not applicable
    Location
    Kyusyu, Japan
    Status
    Not applicable
    Showing {first} - {last} of {total} Results